ClinicalTrials.gg
RecruitingNCT07459101UNITED-4Updated Oct 23, 2026

UNIty-Based MR-Linac Guided Adaptive RadioThErapy for High GraDe Glioma-4

An interventional study of Dose painting + Reduced Margins in Glioblastoma (GBM) and Astrocytoma, Grade IV, sponsored by Sunnybrook Health Sciences Centre. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Sunnybrook Health Sciences Centre · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.
Updated Oct 23, 2026Enrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 118 studies in Glioblastoma with a site in Canada — 17 open to participants now, 34 under way, 5 of them phase 3. Glioblastoma · Canada.

Planned enrollment
44th of 111
120 · median 74
Started
2025
with 7 others
No phase
14 of 118
3 open now
Primary completion
2029-10
later than 32 of 33 live
Registered
117th of 118
by date
Lead sponsor
9 of 118
Sunnybrook Health Sciences Centre

Among the 118 studies in Glioblastoma with a site in Canada, this one is the 44th largest by planned enrollment of the 111 interventional ones that give a count, is one of 8 that started in 2025, is one of 14 with no phase, reaches primary completion later than 32 of the 33 other live ones, and was the 117th registered.

Glioblastoma

2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

17 of the 118 studies in Glioblastoma with a site in Canada are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 118 studies in Glioblastoma with a site in Canada, or all of them as a file.
02

Study summary

This study builds on the results of prior studies (UNITED and UNITED-3). The goal of UNITED-4 is to test whether an adaptive radiation therapy (RT) therapy approach ('dose painting'), with reduced margins, impacts approach in participants with glioblastoma impacts local control compared to standard non-adaptive RT approach. The main questions of the study are to see how this adaptive RT approach with reduced margins compares to standard RT in terms of:

  • Local control
  • Overall and progression-free survival
  • Patterns of failure
  • Toxicity, Neurological Function, and Quality of Life
  • Longitudinal imaging features
Read the detailed description

The UNITED-4 study is for people diagnosed with glioblastoma (GBM) or other high-grade (aggressive) brain tumors. These tumors are typically treated with radiation therapy combined with a chemotherapy agent called temozolomide. Standard radiation for these tumours uses a wide margin around the tumor to ensure that all areas potentially at risk for the presence of cancer cells are targeted, but this approach can also damage healthy brain tissue.

The UNITED-4 trial uses a new machine called an MR-Linac, which combines a radiation machine with an magnetic resonance imaging (MRI) scanner, allowing doctors to take daily images during treatment and adjust the radiation plan in real-time. This study will personalize treatment based on fluid-attenuated inversion recovery (FLAIR) MRI imaging that shows where cancer cells might be spreading while using smaller treatment margins to protect more of the normal brain. Patients will receive either 30 treatments over 6 weeks or 15 treatments over 3 weeks, with different radiation doses delivered simultaneously to high-risk areas (tumour) and lower-risk areas (normal brain). The goal of this study is to determine if this approach maintains cancer control while potentially reducing side effects and improving quality of life compared to standard treatments. Risks include radiation side effects (expected to be no worse than standard treatment) and a possibility of tumor recurrence at treatment edges.

The study will enroll 60 patients over 24 months at Sunnybrook Health Sciences Centre.

03

Conditions studied

  • Glioblastoma (GBM)
  • Astrocytoma, Grade IV

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histopathologically confirmed, based on or surgical resection, glioblastoma or WHO grade 4 astrocytoma (IDH wild type or mutant)
  • Deemed clinically appropriate for concurrent chemoradiotherapy (with temozolomide) with definitive/radical intent
  • Biopsy or surgical resection performed ≤ 12 weeks prior to study entry
  • Expected survival ≥ 12 weeks
  • performance status of 0, 1 or 2
  • Sufficient estimated (eGFR) of ≥ 30 mL/ min/1.73 m2 to allow administration of gadolinium-based contrast agent; patients with eGFR \< 30 mL/min/1.73 m2 not on dialysis may be allowed on the study after discussion of risks and benefits and approval by study neuroradiologist(s)
  • Completed written
  • Patient must be accessible for treatment and follow-up
  • Patients with multifocal or multicentric disease will be allowed per the discretion of the radiation oncologist

Exclusion criteria

Exclusion Criteria:

  • to MRI examination as per standard MRI screening policy
  • Contraindication to Gadolinium-based contrast media
  • Enhancing disease involving any part of the brainstem on post-gadolinium T1-weighted MRI imaging for patients being treated using the short-course 15-fraction regimen
  • Inability to lie flat in a supine position for at least 30 minutes
  • Inability to tolerate immobilization in a head thermoplastic mask
  • Patients > 140 kg and/or a circumference > 60 cm (MRI scanner weight and bore size limits)
  • Prior therapeutic cranial irradiation
  • dissemination of disease
  • History of other with the exception of adequately treated non-melanoma skin cancer, or curatively treated other solid tumours with no evidence of disease for ≥ 2 years
  • Patients with any condition (e.g. psychological, geographical, etc.) that does not permit compliance with the protocol
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Adaptive RT (Dose Painting)

    Participants in this arm will have radiation (with reduced margins) delivered using a dose painting approach

    Radiation: Dose painting + Reduced Margins

Interventions

  • RadiationDose painting + Reduced Margins

    Reduced margins using a dose painting approach

06

What researchers measure

Primary outcomes

  1. Disease worsening at 6 months

    Time frame: From RT start to 6 months after RT

Secondary outcomes

  1. Overall survival

    Time frame: Throughout study participation, anticipated 0-25 months

  2. Type of progression

    Whether the progression occurred at local, marginal, or distant location

    Time frame: Throughout study participation, anticipated 0-25 months

  3. Number of participants with RT-related adverse events as assessed by CTCAE v5.0

    Acute (within 3 months of RT completion) and late (\> 3 months of RT completion) effects will be assessed

    Time frame: Throughout study participation, anticipated 0-25 months

  4. Neurological Function

    Will be assessed by your treating doctor, using the Neurological Assessment in Neuro-Oncology (NANO) scale

    Time frame: Throughout study participation, anticipated 0-25 months

  5. Imaging features as correlates of treatment outcomes

    Time frame: Throughout study participation, anticipated 0-25 months

  6. Changes in the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30)

    This is one of the questionnaires that will be used to qualitatively assess the changes to your quality of life (neurological function, symptoms, and overall status), during your participation on the study. A higher scale score represents a higher response level with regards to the measured item.

    Time frame: Throughout study participation, anticipated 0-25 months

  7. Changes in the European Organisation for Research and Treatment of Cancer Brain Cancer Module (EORTC QLQ-BN20)

    This questionnaire is used together with QLQ-C30 to qualitatively assess changes in your symptoms during your participation on the study. A higher scale score represents more, or more severe, symptoms.

    Time frame: Throughout study participation, anticipated 0-25 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Oct 2029, 49 months after the start.

Of 133 non-industry interventional studies with no phase under Glioblastoma, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 97. This study's planned 49 months is close to that.

Counting every sponsor, half of 151 studies reached it within 54 months; a quarter within 36 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2025
First posted
Mar 9, 2026
StartActual
Sep 10, 2025
Primary completionEst.
Oct 2029
CompletionEst.
Oct 2030
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
60→120
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Enrollment 60→120

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07459101
Responsible party
Sponsor
First posted
Mar 9, 2026
Start date
Sep 10, 2025
Primary completion
Oct 2029 (estimated)
Completion
Oct 2030 (estimated)
Last update
Oct 23, 2026

Study contacts

Hanbo Chen, MD
Contact
hanbo.chen@sunnybrook.ca
416-480-6100

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion